Technical Analysis for BCLI - Brainstorm Cell Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.27 | 0.56% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.56% | |
| NR7 | Range Contraction | 0.56% | |
| Narrow Range Bar | Range Contraction | 0.56% | |
| Wide Bands | Range Expansion | 0.56% | |
| Up 3 Days in a Row | Strength | 0.56% | |
| Up 4 Days in a Row | Strength | 0.56% | |
| Oversold Stochastic | Weakness | 0.56% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 1.37% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.37% | |
| Narrow Range Bar | Range Contraction | 1.37% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Down 3% | about 1 hour ago |
| Shooting Star Candlestick Entry | about 1 hour ago |
| Fell Below Previous Day's Low | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/05/2024
Brainstorm Cell Therapeutics Inc. Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Bone Stem Cell Parkinson's Disease Neurodegenerative Diseases Multiple Sclerosis Medical Research Amyotrophic Lateral Sclerosis Degenerative Disease Storm Bone Marrow Neurochemistry Neurodegenerative Disorders Induced Stem Cells Adult Stem Cell Cell Product Neuron Mesenchymal Stem Cell Cell Encapsulation Hadassah Medical Center Vascular Endothelial Growth Factor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.8905 |
| 52 Week Low | 1.05 |
| Average Volume | 88,005 |
| 200-Day Moving Average | 5.29 |
| 50-Day Moving Average | 2.36 |
| 20-Day Moving Average | 1.54 |
| 10-Day Moving Average | 1.23 |
| Average True Range | 0.21 |
| RSI (14) | 25.93 |
| ADX | 35.4 |
| +DI | 11.62 |
| -DI | 27.25 |
| Chandelier Exit (Long, 3 ATRs) | 1.62 |
| Chandelier Exit (Short, 3 ATRs) | 1.67 |
| Upper Bollinger Bands | 2.21 |
| Lower Bollinger Band | 0.88 |
| Percent B (%b) | 0.29 |
| BandWidth | 86.42 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.38 |
| MACD Histogram | 0.0317 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.34 | ||||
| Resistance 3 (R3) | 1.34 | 1.32 | 1.32 | ||
| Resistance 2 (R2) | 1.32 | 1.30 | 1.32 | 1.32 | |
| Resistance 1 (R1) | 1.29 | 1.29 | 1.31 | 1.29 | 1.31 |
| Pivot Point | 1.27 | 1.27 | 1.28 | 1.27 | 1.27 |
| Support 1 (S1) | 1.24 | 1.25 | 1.26 | 1.24 | 1.21 |
| Support 2 (S2) | 1.22 | 1.24 | 1.22 | 1.20 | |
| Support 3 (S3) | 1.19 | 1.22 | 1.20 | ||
| Support 4 (S4) | 1.19 |
